ir_header
Current stock value

Last updated on Aug 29, 2014 1:54 PM ET

NASDAQ : SPHS 2.96   
- 0.12
  
3.89%

Fact Sheet

PDF Download the Sophiris Fact Sheet


Investor Presentation

PDF Download the Sophiris Investor Presentation


Investors

Sophiris Bio Inc. (NASDAQ: SPHS) is a biopharmaceutical company developing a clinical-stage, targeted treatment for the symptoms of benign prostatic hyperplasia (BPH or enlarged prostate), which it believes is an unsatisfied market with significant market potential. Sophiris’ lead candidate for BPH, PRX302, is designed to be as efficacious as pharmaceuticals, less invasive than the surgical interventions, and without the sexual side effects seen with existing treatments. Sophiris is currently enrolling patients in the PLUS 1 Phase III clinical study using PRX302 for the treatment of symptoms of BPH.

View all »   RSSRecent Releases

Aug 7, 2014
Sophiris Bio Reports Second Quarter Financial Results and Key Operational and Financial Highlights

May 22, 2014
Sophiris Bio to Present at the Jefferies 2014 Global Healthcare Conference